Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Clinical Trial

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1753300

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1753300

Angiosarcoma Treatment

PUBLISHED:
PAGES: 390 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Angiosarcoma Treatment Market to Reach US$364.1 Million by 2030

The global market for Angiosarcoma Treatment estimated at US$283.1 Million in the year 2024, is expected to reach US$364.1 Million by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Hemangiosarcoma Type, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$205.7 Million by the end of the analysis period. Growth in the Lymphangiosarcoma Type segment is estimated at 5.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$77.1 Million While China is Forecast to Grow at 7.7% CAGR

The Angiosarcoma Treatment market in the U.S. is estimated at US$77.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$74.1 Million by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Angiosarcoma Treatment Market - Key Trends & Drivers Summarized

Why Is Angiosarcoma Gaining Greater Visibility in Oncological Research and Practice?

Angiosarcoma, a rare and aggressive cancer of the blood or lymphatic vessels, is increasingly becoming a focal point in oncology due to its highly invasive nature, diagnostic complexity, and the historically limited treatment options available. Though it accounts for a very small percentage of soft tissue sarcomas, its poor prognosis and rapid metastatic potential have prompted researchers and clinicians to prioritize more effective and individualized therapies. One of the factors contributing to its growing visibility is the increasing prevalence of risk factors such as radiation exposure, chronic lymphedema, and aging populations-each of which has been linked to secondary or sporadic angiosarcoma development. Moreover, improvements in cancer surveillance, diagnostic imaging, and biopsy techniques have led to a slight uptick in case detection, even in early stages, allowing for more opportunities to intervene clinically.

The challenges of managing angiosarcoma have spurred a collective response from academic institutions, biotech firms, and public health entities to better understand its molecular behavior. With traditional treatments offering limited survival benefits, the need for innovative therapies is urgent and widely recognized. Additionally, global patient advocacy groups focusing on rare cancers are playing an essential role in raising awareness, mobilizing funding for research, and pushing for inclusion of angiosarcoma in large-scale oncological studies. The digital health revolution is also playing a part, with online registries and patient data platforms contributing valuable insights into treatment responses, recurrence patterns, and survival trends. These evolving trends underscore a broader shift toward rare cancer inclusion in oncology research, positioning angiosarcoma as a priority area for development of targeted and precision-based therapies.

How Are Treatment Modalities Evolving in Response to Angiosarcoma’s Complexity?

Treatment strategies for angiosarcoma have become more diversified and nuanced in recent years, moving beyond the traditional reliance on surgery and chemotherapy. Given the tumor’s propensity for rapid local invasion and distant metastasis, a multidisciplinary approach is increasingly being adopted, combining systemic therapies with localized interventions for better disease control. Surgery remains a cornerstone for localized tumors, particularly when complete resection with negative margins is achievable. However, recurrence rates remain high, and as such, adjuvant therapies are critical to extending progression-free intervals. Radiation therapy is often used in combination with surgery to reduce local recurrence, particularly in cases involving the scalp or breast, where wide surgical margins are difficult to achieve.

Systemic treatment, however, is where the most significant advancements are occurring. While anthracycline-based regimens have traditionally been used, their toxicity and limited efficacy have led researchers to explore newer options. Targeted therapies, particularly those that inhibit angiogenesis pathways such as VEGF, have shown promise in early-phase studies. Drugs like pazopanib and sorafenib are being evaluated for their ability to interfere with tumor vascularization, a hallmark of angiosarcoma biology. Furthermore, immunotherapy is emerging as a viable option. Immune checkpoint inhibitors, particularly those targeting PD-1 and PD-L1, are being tested in clinical trials, with some patients showing durable responses. Personalized medicine is also gaining traction, with next-generation sequencing being used to identify actionable mutations and guide treatment choices. These developments mark a transition from a one-size-fits-all model to a more personalized, biology-driven approach that holds promise for improving outcomes in a notoriously difficult-to-treat cancer.

What Are the Major Obstacles and Opportunities in Advancing Angiosarcoma Treatment?

Despite recent progress, the road to effective angiosarcoma treatment is still fraught with significant challenges. The foremost issue is the rarity of the disease, which makes it difficult to recruit sufficient patient numbers for large, statistically robust clinical trials. This limitation hampers the development of new therapies and often forces oncologists to extrapolate treatment plans from studies on other, more common soft tissue sarcomas. Additionally, the biological heterogeneity of angiosarcoma-manifesting differently depending on whether it arises in the skin, liver, heart, or breast-means that a treatment effective for one subtype may not work for another. The aggressive nature of the disease also restricts the therapeutic window; many patients present at an advanced stage, leaving little time for experimental interventions or multiple lines of treatment.

Nevertheless, the same rarity that poses a challenge is also opening new avenues for innovation. Orphan drug incentives provided by regulatory agencies are encouraging pharmaceutical companies to invest in treatments for ultra-rare cancers like angiosarcoma. Collaborative networks are also being formed, linking oncology centers across countries to share data, treatment protocols, and patient outcomes. These networks facilitate multi-institutional studies and allow for more rapid accumulation of evidence. Moreover, advances in bioinformatics and artificial intelligence are enabling researchers to derive insights from small datasets, potentially identifying novel biomarkers or drug targets. Another promising area is drug repurposing, where existing cancer therapies are screened for efficacy against angiosarcoma in preclinical models, accelerating the path to clinical application. With the rise of genomic medicine and increasing global collaboration, the treatment landscape for angiosarcoma, while still limited, is beginning to show tangible signs of evolution and future promise.

Which Key Factors Are Driving Growth in the Global Angiosarcoma Treatment Market?

The growth in the global angiosarcoma treatment market is being driven by a convergence of scientific progress, patient advocacy, healthcare policy, and strategic investment in rare cancer therapeutics. One of the most important factors is the increasing understanding of tumor genetics and angiogenesis pathways, which is helping to identify novel targets for drug development. The surge in next-generation sequencing capabilities has enabled more frequent identification of mutations in pathways like MYC amplification and PI3K-AKT signaling, which could be exploited for targeted therapy. This scientific momentum is being matched by supportive policy frameworks, including orphan drug designation programs in major markets such as the United States and European Union, which offer incentives like tax credits, fast-track approvals, and market exclusivity to drug developers working in rare disease areas.

Patient-driven momentum is also a key growth factor. With social media and digital health tools, angiosarcoma patients are more connected than ever before, forming communities that support clinical trial recruitment and educate the public and clinicians alike. This increased visibility is translating into better funding for research and faster patient enrollment in experimental treatment protocols. On the commercial side, biotechnology firms specializing in rare cancers are increasingly entering the market, either through independent research or via partnerships with academic centers. The interest from investors in orphan oncology pipelines is strong, as these therapies often command premium pricing and benefit from less competitive pressure. Additionally, global improvements in cancer care infrastructure-especially in emerging markets-are expanding access to advanced diagnostics and treatment, further widening the market base. Altogether, the combination of technological, regulatory, and grassroots advancements is fueling steady and meaningful growth in the angiosarcoma treatment market.

SCOPE OF STUDY:

The report analyzes the Angiosarcoma Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Hemangiosarcoma Type, Lymphangiosarcoma Type, Parenchymal Angiosarcoma Type); Treatment (Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment, Other Treatments); End-Use (Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use, Online Pharmacies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Eisai Co., Ltd.
  • Genentech (Roche Group)
  • GlaxoSmithKline (GSK)
  • Ipsen
  • Johnson & Johnson
  • Merck & Co. (MSD)
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Sanofi
  • Seattle Genetics (Seagen)
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical
  • Spectrum Pharmaceuticals
  • Syntrix Biosystems
  • Zymeworks Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP36166

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Angiosarcoma Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Rare and Aggressive Vascular Tumors Spurs Demand for Targeted Angiosarcoma Treatments
    • Advancements in Genomic and Molecular Profiling Strengthen the Business Case for Precision Oncology Approaches
    • Here's How Increased Inclusion in Rare Cancer Research Pipelines Propels Growth in Experimental and Targeted Therapies
    • Growing Awareness Among Oncologists and Pathologists Expands the Addressable Pool of Diagnosed Angiosarcoma Patients
    • Surge in Immunotherapy and Checkpoint Inhibitor Trials Throws the Spotlight on Next-Generation Therapeutics for Angiosarcoma
    • Here's the Story: FDA Orphan Drug Designation and Accelerated Approval Pathways Fuel Innovation in Drug Development
    • Expansion of Molecular Tumor Boards Strengthens Multi-Disciplinary Treatment Planning and Therapy Selection
    • Increasing Use of Off-Label Chemotherapy and Radiotherapy Protocols Sustains Demand for Supportive Care Infrastructure
    • Growing Role of AI in Rare Cancer Detection and Treatment Optimization Enhances Early Identification and Personalized Care
    • Rising Availability of Genetic Testing and Companion Diagnostics Supports Stratified Therapy Approaches in Angiosarcoma
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Angiosarcoma Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Angiosarcoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Angiosarcoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hemangiosarcoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hemangiosarcoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hemangiosarcoma Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Lymphangiosarcoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Lymphangiosarcoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Lymphangiosarcoma Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Parenchymal Angiosarcoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Parenchymal Angiosarcoma Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Parenchymal Angiosarcoma Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Online Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Radiotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Radiotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Radiotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Targeted Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Targeted Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Targeted Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Immunotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Immunotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Immunotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Angiosarcoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • JAPAN
    • Angiosarcoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • CHINA
    • Angiosarcoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • EUROPE
    • Angiosarcoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Angiosarcoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Angiosarcoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • FRANCE
    • Angiosarcoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • GERMANY
    • Angiosarcoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Angiosarcoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Angiosarcoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Angiosarcoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Angiosarcoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Angiosarcoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • INDIA
    • Angiosarcoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Angiosarcoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Angiosarcoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Angiosarcoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Angiosarcoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Angiosarcoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Angiosarcoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030
  • AFRICA
    • Angiosarcoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Angiosarcoma Treatment by Type - Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Angiosarcoma Treatment by Type - Percentage Breakdown of Value Sales for Hemangiosarcoma Type, Lymphangiosarcoma Type and Parenchymal Angiosarcoma Type for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Angiosarcoma Treatment by End-Use - Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Angiosarcoma Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use and Online Pharmacies End-Use for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Angiosarcoma Treatment by Treatment - Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Angiosarcoma Treatment by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiotherapy Treatment, Chemotherapy Treatment, Targeted Therapy Treatment, Immunotherapy Treatment and Other Treatments for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!